CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon acquired 10,642 shares of the stock in a transaction dated Thursday, October 5th. The stock was bought at an average cost of $4.00 per share, with a total value of $42,568.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Thursday, September 7th, Neil Gagnon acquired 6,496 shares of CareDx stock. The stock was bought at an average cost of $3.05 per share, with a total value of $19,812.80.
- On Monday, August 28th, Neil Gagnon acquired 21,448 shares of CareDx stock. The stock was bought at an average cost of $2.77 per share, with a total value of $59,410.96.
- On Friday, August 25th, Neil Gagnon acquired 35,119 shares of CareDx stock. The stock was bought at an average cost of $2.92 per share, with a total value of $102,547.48.
- On Monday, July 24th, Neil Gagnon acquired 1,486 shares of CareDx stock. The stock was bought at an average cost of $1.23 per share, with a total value of $1,827.78.
Shares of CareDx, Inc. (NASDAQ:CDNA) opened at 5.62 on Monday. The company’s market capitalization is $126.68 million. CareDx, Inc. has a 52 week low of $0.76 and a 52 week high of $6.69. The company’s 50 day moving average price is $3.18 and its 200-day moving average price is $1.69.
CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, meeting analysts’ consensus estimates of ($0.19). CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. The firm had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.87 million. Analysts anticipate that CareDx, Inc. will post ($0.82) earnings per share for the current fiscal year.
WARNING: “Insider Buying: CareDx, Inc. (CDNA) Major Shareholder Buys $42,568.00 in Stock” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/09/insider-buying-caredx-inc-cdna-major-shareholder-buys-42568-00-in-stock.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDNA. Stonepine Capital Management LLC acquired a new position in CareDx in the second quarter valued at approximately $212,000. Royce & Associates LP lifted its stake in CareDx by 23.5% during the first quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock worth $737,000 after purchasing an additional 100,111 shares in the last quarter. Finally, Gagnon Securities LLC lifted its stake in CareDx by 2.9% during the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after purchasing an additional 57,954 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.
Several research firms have recently issued reports on CDNA. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Wednesday, September 27th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Piper Jaffray Companies reissued an “overweight” rating and set a $7.00 price target (up from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. Finally, Zacks Investment Research lowered CareDx from a “buy” rating to a “hold” rating in a research note on Monday, September 11th.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.